Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.

Mueller D, Gandjour A.

Value Health. 2009 Nov-Dec;12(8):1106-17. doi: 10.1111/j.1524-4733.2009.00577.x. Epub 2009 Aug 10.

PMID:
19706151
2.

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.

Mueller D, Gandjour A.

Appl Health Econ Health Policy. 2008;6(2-3):113-35. doi: 10.2165/00148365-200806020-00004.

PMID:
19231905
3.

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.

Schwenkglenks M, Lippuner K.

Osteoporos Int. 2007 Nov;18(11):1481-91. Epub 2007 May 26.

PMID:
17530156
4.

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Nayak S, Roberts MS, Greenspan SL.

Ann Intern Med. 2011 Dec 6;155(11):751-61. doi: 10.7326/0003-4819-155-11-201112060-00007.

5.

Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis.

Mueller D, Weyler E, Gandjour A.

Pharmacoeconomics. 2008;26(6):513-36.

PMID:
18489201
6.

Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.

Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y.

Value Health. 2012 Jan-Feb;15(1 Suppl):S20-8. doi: 10.1016/j.jval.2011.11.015.

PMID:
22265062
7.

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

Tosteson AN, Burge RT, Marshall DA, Lindsay R.

Am J Manag Care. 2008 Sep;14(9):605-15.

8.
9.

Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.

Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL.

J Am Geriatr Soc. 2005 Oct;53(10):1697-704.

PMID:
16181168
10.

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.

Mueller D, Gandjour A.

Appl Health Econ Health Policy. 2011 Jul 1;9(4):259-73. doi: 10.2165/11587360-000000000-00000. Erratum in: Appl Health Econ Health Policy. 2011 Sep 1;9(5):348.

PMID:
21682353
11.

Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.

Ito K, Blinder VS, Elkin EB.

J Clin Oncol. 2012 May 1;30(13):1468-75. doi: 10.1200/JCO.2011.38.7001. Epub 2012 Feb 27.

12.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
13.

Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.

Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ 3rd, Bauer DC, Ensrud KE.

JAMA. 2007 Aug 8;298(6):629-37.

PMID:
17684185
14.

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.

Schousboe JT, Nyman JA, Kane RL, Ensrud KE.

Ann Intern Med. 2005 May 3;142(9):734-41.

PMID:
15867405
15.

Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.

Nayak S, Roberts MS, Greenspan SL.

PLoS One. 2012;7(3):e32879. doi: 10.1371/journal.pone.0032879. Epub 2012 Mar 13.

16.

Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in postmenopausal women from the general population: a cost-effectiveness analysis.

Marín F, López-Bastida J, Díez-Pérez A, Sacristán JA; ECOSAP DXA Substudy Group Investigators.

Calcif Tissue Int. 2004 Mar;74(3):277-83. Epub 2003 Dec 23.

PMID:
14708042
17.

The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.

Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP.

Value Health. 2010 Jan-Feb;13(1):46-54. doi: 10.1111/j.1524-4733.2009.00666.x. Epub 2009 Oct 26.

PMID:
19883401
18.

Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women.

Panichkul S, Panichkul P, Sritara C, Tamdee D.

Gynecol Obstet Invest. 2006;62(2):89-96. Epub 2006 Apr 20.

PMID:
16636570
19.

Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women.

Nagata-Kobayashi S, Shimbo T, Fukui T.

J Bone Miner Metab. 2002;20(6):350-7.

PMID:
12434163
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk